Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rats

In summary, Fortunellin alleviated lipid deposition and immune disorders in young rats with NAFLD through the activation of AMPK.

Authors

Institutions

Publication Details

Journal
Endocrine Metabolic & Immune Disorders - Drug Targets
Published
2025-09-01
DOI
https://doi.org/10.2174/0118715303391165250828111133
Citations
2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rats

Na Qin, Ping Nan
2 citations
Endocrine Metabolic & Immune Disorders - Drug Targets
Liver Disease Diagnosis and Treatment
2.71
article

Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rats

Na Qin, Ping Nan
article en
2 citations

Abstract

In summary, Fortunellin alleviated lipid deposition and immune disorders in young rats with NAFLD through the activation of AMPK.

Endocrine Metabolic & Immune Disorders - Drug TargetsVol. 25
Changzhi Medical College (CN)
Openalex Percentile: Top 9%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rats — Na Qin, Ping Nan · Endocrine Metabolic & Immune Disorders - Drug Targets (2025) | TGRS Research Map | TGRS